Omipalisib 10 mg | 99.16%
TargetMol

GSK2126458 is a small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity.
More Information Supplier PageGSK2126458 is a small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity.
More Information Supplier PageXMD17-109 is a new selective ERK-5 inhibitor (EC50: 4.2 uM, HEK293 cells).
More Information Supplier PageXMD17-109 is a new selective ERK-5 inhibitor (EC50: 4.2 uM, HEK293 cells).
More Information Supplier PageXMD17-109 is a new selective ERK-5 inhibitor (EC50: 4.2 uM, HEK293 cells).
More Information Supplier PageAtglistatin is a highly effective, specific and competitive ATGL inhibitor with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, and no toxicity when the concentration up to 50 μM.
More Information Supplier PageAtglistatin is a highly effective, specific and competitive ATGL inhibitor with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, and no toxicity when the concentration up to 50 μM.
More Information Supplier PageThe N-dealkylated metabolite (M1) of Atazanavir, a HIV protease inhibitor.
More Information Supplier PageThe N-dealkylated metabolite (M1) of Atazanavir, a HIV protease inhibitor.
More Information Supplier PageThe N-dealkylated metabolite (M1) of Atazanavir, a HIV protease inhibitor.
More Information Supplier PageKobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; shows potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.
More Information Supplier Page